Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (OPUS)
Neoplasm Metastasis, Colorectal Cancer
About this trial
This is an interventional treatment trial for Neoplasm Metastasis focused on measuring FOLFOX-4, Cetuximab, First-line mCRC, EGFR positive, metastatic CRC
Eligibility Criteria
Inclusion Criteria: First-line mCRC EGFR positive Bi-dimensional measurable index lesion Exclusion Criteria: Previous exposure to EGFR-targeting therapy Previous oxaliplatin-based therapy Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment Radiotherapy Surgery Any other investigational drug in the 30 days before randomization Brain metastasis and/or leptomeningeal disease Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Cetuximab Plus FOLFOX-4
FOLFOX-4 Alone